---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095749"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:46:53.091862+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MindMed Q2 net loss narrows to $5.9M; cash at $243M to fund Phase 3 in GAD

## Summary
- Net loss of $5.9 million, down from $29.1 million in Q2 2023, primarily due to warrant fair value changes.
- Cash and equivalents of $243.1 million as of June 30, 2024; plus ~$70M net from July 2024 offering, extending runway into 2027.
- Completed end-of-Phase 2 meeting with FDA; first Phase 3 trial (Voyage) for MM120 ODT in GAD to start H2 2024 with topline in H1 2026.
- Expanding pipeline: registrational study (Emerge) for MM120 ODT in MDD planned for H1 2025, topline H2 2026.
- New USPTO patent issued covering MM120 ODT formulation and method of treatment, extending IP protection through 2041.

## SEC filing metadata
- accession: 0000950170-24-095749
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017024095749/0000950170-24-095749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017024095749/mnmd-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095749
- JSON: https://secwatch.observer/filing/0000950170-24-095749.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.